Journal Mobile Options
Table of Contents
Vol. 68, No. 4-6, 2005
Issue release date: August 2005
Section title: Laboratory Investigation
Oncology 2005;68:538–547
(DOI:10.1159/000086998)

Inhibitors of Epidermoid Growth Factor Receptor Suppress Cell Growth and Enhance Chemosensitivity of Nasopharyngeal Cancer Cells in vitro

Hsu C.-H.a,e · Gao M.a,e · Chen C.-L.b,d · Yeh P.-Y.a,e · Cheng A.-L.a,c,e
Departments of aOncology, bPathology and cInternal Medicine, National Taiwan University Hospital, dDepartment of Pathology, Wanfang Hospital and Taipei Medical University, and eCancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Laboratory Investigation

Received: 8/12/2004
Accepted: 11/14/2004
Published online: 8/17/2005
Issue release date: August 2005

Number of Print Pages: 10
Number of Figures: 7
Number of Tables: 0

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL

Abstract

Objective: Epidermoid growth factor receptor (EGFR, HER1) is overexpressed in a majority of head-and-neck cancers, including nasopharyngeal carcinoma (NPC). Although EGFR inhibitors appear to be effective for some head-and-neck cancers, their efficacy in NPC remains unclear. Methods: The effect of EGFR-specific tyrosine kinase inhibitors, including PD153035 and ZD1839, were studied in NPC-TW01, NPC-TW04, and HONE1 cell lines. The effect of combining EGFR inhibitors with cytotoxic agents was evaluated in NPC-TW04 cells. Results: All three NPC cell lines expressed EGFR. PD153035 and ZD1839 inhibited the growth of NPC cells with IC50s around 10 and 20 µM, respectively. These inhibitors, however, effectively suppressed ligand-stimulated EGFR activation in NPC cells with a much lower concentration (≧0.1 µM). The growth-suppression activity of EGFR inhibitors was closely associated with suppression of AKT phosphorylation. LY294002, a phosphatidylinositol-3 kinase (P13K)/AKT inhibitor, did suppress the growth of NPC cells. Pretreatment of EGFR inhibitors by 24 h significantly enhanced the cytotoxic effect of doxorubicin, paclitaxel, cisplatin, and 5-fluororuacil in NPC-TW04 cells. Conclusions: Our data indicate that inhibition of EGFR activation is not sufficient to induce growth inhibition in NPC cells in vitro. EGFR inhibitors may be useful adjuncts in treating NPC when combined with conventional anticancer drugs.

© 2005 S. Karger AG, Basel


  

Author Contacts

Ann-Lii Cheng, MD, PhD
Department of Internal Medicine, National Taiwan University Hospital
No. 7 Chung-Shan South Road, Taipei 10002 (Taiwan)
Tel. +886 2 2312 3456, ext. 7251, Fax +886 2 2371 1174
E-Mail andrew@ha.mc.ntu.edu.tw

  

Article Information

Received: August 12, 2004
Accepted after revision: November 14, 2004
Published online: July 20, 2005
Number of Print Pages : 10
Number of Figures : 7, Number of Tables : 0, Number of References : 52

  

Publication Details

Oncology (International Journal of Cancer Research and Treatment)

Vol. 68, No. 4-6, Year 2005 (Cover Date: Released August 2005)

Journal Editor: D.L. Trump, Buffalo, N.Y.
ISSN: 0030–2414 (print), 1423–0232 (Online)

For additional information: http://www.karger.com/ocl


Article / Publication Details

First-Page Preview
Abstract of Laboratory Investigation

Received: 8/12/2004
Accepted: 11/14/2004
Published online: 8/17/2005
Issue release date: August 2005

Number of Print Pages: 10
Number of Figures: 7
Number of Tables: 0

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.